
Season's Greetings
TWINCORE wishes you happy holidays and a successful new year

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.

TWINCORE wishes you happy holidays and a successful new year

zukunft.niedersachsen provides €2.7 million in funding for joint project on rare diseases

€100,000 from the German Society for Parkinson's Disease and Movement Disorders
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Chaturvedi M, Bartz A, Denkinger C, Klett-Tammen C, Kretzschmar M, Kuhlmann A, Lange B, Marx F, Mikolajczyk R, Monsef I, Nguyen H, Suer J, Skoetz N, Jaeger V, Karch A
Strunz B, Zhan Q, Khera T, Hengst J, Jankovic M, Deterding K, Niehrs A, Cornberg M, Xu C, Wedemeyer H, Björkström N
Heinrich S, Ten Thoren P, Behrendt P, Hagenah J, Wedemeyer H, Potthoff A, Maasoumy B
The project is developing methods to specifically transport antibiotics into cells such as alveolar macrophages, which are important in Mycobacterium tuberculosis infections. The aim is to overcome resistance and reduce side effects.
This project focuses on lung infections such as influenza, COVID-19, pneumonia and tuberculosis in order to improve diagnostics, patient stratification and therapy. RNA molecules and metabolites are being investigated as biomarkers and complementary therapies.
We develop high-throughput screening assays to identify antiviral molecules against RSV and SARS-CoV-2. We use compound libraries, investigate new mechanisms of action and strive for innovative therapies.
Population genetic studies show that genetic variability between bacterial strains can influence the evolution of antimicrobial resistance. Using automated laboratory evolution (ALE), we are investigating how genetic backgrounds control AMR evolution.
There are currently no events.

